The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effective Treatment of Edema and Endothelial Barrier Dysfunction With Imatinib
Open accessAbstract
Background—: Tissue edema and endothelial barrier dysfunction as observed in sepsis and acute lung injury carry high morbidity and mortality, but currently lack specific therapy. In a recent case report, we described fast resolution of pulmonary edema on treatment with the tyrosine kinase inhibitor imatinib through an unknown mechanism. Here, we explored the effect of imatinib on endothelial barrier dysfunction and edema formation. Methods and Results—: We evaluated the effect of imatinib on endothelial barrier function in vitro and in vivo. In human macro- and microvascular endothelial monolayers, imatinib attenuated endothelial barrier dysfunction induced by thrombin and histamine. Small interfering RNA knock-downs of the imatinib-sensitive kinases revealed that imatinib attenuates endothelial barrier dysfunction via inhibition of Abl-related gene kinase (Arg/Abl2), a previously unknown mediator of endothelial barrier dysfunction. Indeed, Arg was activated by endothelial stimulation with thrombin, histamine, and vascular endothelial growth factor. Imatinib limited Arg-mediated endothelial barrier dysfunction by enhancing Rac1 activity and enforcing adhesion of endothelial cells to the extracellular matrix. Using mouse models of vascular leakage as proof-of-concept, we found that pretreatment with imatinib protected against vascular endothelial growth factor–induced vascular leakage in the skin, and effectively prevented edema formation in the lungs. In a murine model of sepsis, imatinib treatment (6 hours and 18 hours after induction of sepsis) attenuated vascular leakage in the kidneys and the lungs (24 hours after induction of sepsis). Conclusions—: Thus, imatinib prevents endothelial barrier dysfunction and edema formation via inhibition of Arg. These findings identify imatinib as a promising approach to permeability edema and indicate Arg as novel target for edema treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843
Broken Barriers: A New Take on Sepsis Pathogenesis
Goldenberg, N. M., Steinberg, B. E., Slutsky, A. S., & Lee, W. L. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002011 · Cited by 324
Cited by
Role of Pore-Forming Toxins in Bacterial Infectious Diseases
Los, F. C. O., Randis, T. M., Aroian, R. V., & Ratner, A. J. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00052-12 · Cited by 402
Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue
Herrmann, J., Yang, E. H., Iliescu, C. A., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., Grines, C. L., & Marmagkiolis, K. (2016) · Circulation · doi:10.1161/circulationaha.115.018347 · Cited by 329
Langer, V., Vivi, E., Regensburger, D., Winkler, T. H., Waldner, M. J., Rath, T., Schmid, B., Skottke, L., Lee, S., Jeon, N. L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124884 · Cited by 256
Fernandes, D. C., Silva-de-França, F., Pohl, P. C., Eto, S. F., Sardinha, L. R., Lambris, J. D., & Tambourgi, D. V. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113701 · Cited by 3
Metadata
- Authors
- Aman, J., van Bezu, J., Damanafshan, A., Huveneers, S., Eringa, E. C., Vogel, S. M., Groeneveld, A. B. J., Vonk Noordegraaf, A., van Hinsbergh, V. W. M., & van Nieuw Amerongen, G. P.
- Venue
- Circulation
- Published
- 2012-12-04
- Volume
- 126
- Issue
- 23
- Pages
- 2728-2738
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2166569409
- Cited by
- 177
- References
- 2
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effective Treatment of Edema and Endothelial Barrier Dysfunction With Imatinib. https://app.cochat.ai/papers/10.1161/circulationaha.112.134304
- The paper
- Aman, J., van Bezu, J., Damanafshan, A., Huveneers, S., Eringa, E. C., Vogel, S. M., Groeneveld, A. B. J., Vonk Noordegraaf, A., van Hinsbergh, V. W. M., & van Nieuw Amerongen, G. P. (2012). Effective Treatment of Edema and Endothelial Barrier Dysfunction With Imatinib. Circulation. https://doi.org/10.1161/circulationaha.112.134304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.